Login to Your Account



FINANCINGS NEWS

Selecta Biosciences Inc. Wednesday said it raised more than $20 million in equity funding from new and existing investors to advance its lead program, the severe gout drug SEL-212, and its early stage pipeline of antigen-specific immune therapies.

Everything old is new again for Zynerba Pharmaceuticals Inc., which hit the ground running with a $13 million private raise that included Perceptive Advisors LLC and undisclosed high net worth individual investors. Proceeds from the round will be used to develop the Radnor, Pa.-based company's transdermal cannabinoid therapies, believed to be the first of their kind.

DUBLIN – Nextech Invest Ltd. raised $40 million in a first closing of a new oncology fund that has a final target of $100 million. The Zurich-based venture capital firm aims to raise the remainder in the next 12 months.
More FINANCINGS Headlines

Cast Your Vote

Has biotech’s bubble burst?: